{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:34:08Z","timestamp":1775716448429,"version":"3.50.1"},"reference-count":114,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/14728214.2022.2059464","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T08:31:48Z","timestamp":1648456308000},"page":"75-90","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":33,"title":["Epilepsy: expert opinion on emerging drugs in phase 2\/3 clinical trials"],"prefix":"10.1080","volume":"27","author":[{"given":"Amanda W","family":"Pong","sequence":"first","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Ross","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Tyrlikova","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J","family":"Giermek","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya P","family":"Kohli","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef A","family":"Khan","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D","family":"Salgado","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Epilepsy and Sleep Center, Comprehensive Neurology Clinics of Bethesda, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.541802"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13084"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12666"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002253"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107762"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30035-1"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25956"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1807"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000333"},{"key":"cit0010","unstructured":"Diseases NOfR. Lennox Gastaut Syndrome [cited 2021 Dec 23]. Available from: https:\/\/rarediseases.org\/rare-diseases\/lennox-gastaut-syndrome\/"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02474.x"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(01)00300-X"},{"key":"cit0013","unstructured":"Diseases Nof R CDKL5 Deficiency Disorder 2021 [cited 2021 Dec 23]. Available from: https:\/\/rarediseases.org\/rare-diseases\/cdkl5\/"},{"key":"cit0014","volume-title":"Developmental and Epileptic Encephalopathies: emerging Approaches to Treatment","author":"Demarest S","year":"2021"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22124"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy323"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30217-9"},{"issue":"22","key":"cit0018","first-page":"1419","volume":"313","author":"Aicardi J","journal-title":"N Engl J Med"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14854"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00864"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106646"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2619-13.2013"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.02.010"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2015.02.003"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2015.02.007"},{"key":"cit0026","doi-asserted-by":"crossref","unstructured":"Fs NT, Hasegawa S, Watanabe S, et al. Inhibition of Cholesterol 24-hydroxylase is a Novel Pharmacological Strategy for Epilepsy Treatment (P5.264). 2018 [cited 2021 Nov 19]. Available from: https:\/\/n.neurology.org\/content\/90\/15_Supplement\/P5.264","DOI":"10.1212\/WNL.90.15_supplement.P5.264"},{"key":"cit0027","unstructured":"Nishi WS Inhibition of cholesterol 24-hydroxylase improves the survival of a mouse model of epileptic phenotype and modulates extracellular levels of glutamate 2021 [cited 2021 Nov 19]. Available from: https:\/\/www.abstractsonline.com\/pp8\/#!\/4649\/presentation\/25583"},{"key":"cit0028","unstructured":"Hasegawa S, Nishi T, Watanabe S, et al. Takeda Pharmaceutical Co. Ltd. Cholesterol 24-hydroxylase inhibition is a novel pharmacological mechanism that exerts neuroprotective effects against glutamate excitotoxicity in rats 2021 [cited 2021 Nov 19]. Available from: https:\/\/www.abstractsonline.com\/pp8\/#!\/4649\/presentation\/25584"},{"key":"cit0029","unstructured":"Therapeutics O Ovid Therapeutics Announces Phase 1b\/2a Results of OV935\/TAK-935 in Adults with Rare Epilepsies 2021 [cited 2021 Nov 18]. Available from: https:\/\/investors.ovidrx.com\/news-releases\/news-release-details\/ovid-therapeutics-announces-phase-1b2a-results-ov935tak-935\/"},{"issue":"3","key":"cit0030","first-page":"S25","volume":"60","author":"Mantegazza M","year":"2019","journal-title":"Epilepsia"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6100"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1177\/1535759720975750"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.022"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1159\/000517686"},{"key":"cit0035","unstructured":"Stoke. Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1\/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome 2021. [cited 10 Jan 2022]. [updated September 21]. Available from: https:\/\/investor.stoketherapeutics.com\/news-releases\/news-release-details\/stoke-therapeutics-announces-positive-interim-safety-pk-and-csf"},{"key":"cit0036","unstructured":"Therapeutics SP 2021. [cited 2021 Dec 1]. Available from: https:\/\/www.stoketherapeutics.com\/pipeline\/"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133348"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2007.02.064"},{"issue":"3","key":"cit0039","first-page":"669","volume":"140","author":"Griffin A","journal-title":"Brain Journal of Neurology"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1992275"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006432"},{"key":"cit0042","unstructured":"ClinicalTrials GN NIH Clinical Trials.gov 2021. [cited 2022 Jan 10]. Available from: https:\/\/clinicaltrials.gov\/"},{"key":"cit0043","volume-title":"In Sleep. [Updated 2022 Feb 4]. In: StatPearls [Internet].","author":"Samanta D","year":"2022"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02211.x"},{"key":"cit0045","doi-asserted-by":"crossref","unstructured":"Singhal NS, Sullivan JE Continuous spike-wave during slow wave sleep and related conditions [Review]. ISRN neurology. 2014; 619079.","DOI":"10.1155\/2014\/619079"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/0387-7604(95)00076-N"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21169"},{"key":"cit0048","unstructured":"Pipeline BN 2021 [cited 2021 Dec 28]. Available from: https:\/\/www.neurocrine.com\/pipeline\/pipeline-overview\/"},{"key":"cit0049","unstructured":"Pharmaceuticals CT-WAVE 2022 [cited 2022 Jan 7]. Available from: https:\/\/twavestudy.com\/"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106588"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14557"},{"key":"cit0052","unstructured":"ClinicalTrials GN BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures (FIAS) 2021 [cited 2021 Dec 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03474770?term=NCT03474770&draw=2&rank=1"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.96"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13659"},{"key":"cit0055","unstructured":"Trials GNC a study to investigate JNJ-40411813 in combination with levetiracetam in epilepsy. [cited 2021 Dec 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04836559?term=NCT04836559&cond=epilepsy&draw=2&rank=1"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00827-8"},{"key":"cit0057","unstructured":"Newswire CP SK life science initiates phase 3 clinical trial of carisbamate for lennox-gastaut syndrome [cited 2022 Jan 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/sk-life-science-initiates-phase-3-clinical-trial-of-carisbamate-for-lennox-gastaut-syndrome-301455009.html"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13710"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.016"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16725"},{"key":"cit0061","volume-title":"Phase 2b Efficacy and safety of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy (X-TOLE)","author":"French JA","year":"2021"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16832"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S281490"},{"key":"cit0064","first-page":"1","volume":"29","author":"Lattanzi S","year":"2021","journal-title":"Expert Review of Neurotherapeutics"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30399-0"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13705"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32833735cf"},{"key":"cit0068","volume-title":"Infantile Spasms","author":"Smith MS","year":"2021"},{"key":"cit0069","unstructured":"Stroke NIoNDa."},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00170-4"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02870.x"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0188-y"},{"key":"cit0073","unstructured":"rarechromo.org. PCDH19\u2013related epilepsy [cited 2021 Dec 21]. Available from: https:\/\/www.rarechromo.org\/media\/singlegeneinfo\/Single%20Gene%20Disorder%20Guides\/PCDH19-related%20epilepsy%20FTNW.pdf"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1250"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1743678"},{"key":"cit0076","volume-title":"Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-Clustering Epilepsy","author":"Sullivan J","year":"2021"},{"key":"cit0077","unstructured":"Pharmaceuticals M marinus announces successful clinical trial results and declares cdkl5 disorder its lead pediatric orphan epilepsy program for ganaxolone 2017 [cited 2021 Dec 21]. Available from: https:\/\/www.globenewswire.com\/news-release\/2017\/09\/11\/1117414\/0\/en\/Marinus-Announces-Successful-Clinical-Trial-Results-and-Declares-CDKL5-Disorder-Its-Lead-Pediatric-Orphan-Epilepsy-Program-for-Ganaxolone.html"},{"key":"cit0078","unstructured":"Wire B Ganaxolone achieves primary endpoint in phase 3 trial for cdkl5 deficiency disorder (cdd), a rare form of genetic epilepsy 2020 [cited 2021 March 14]. Available from: https:\/\/www.businesswire.com\/news\/home\/20200914005828\/en\/Ganaxolone-Achieves-Primary-Endpoint-in-Phase-3-Trial-for-CDKL5-Deficiency-Disorder-CDD-a-Rare-Form-of-Genetic-Epilepsy"},{"key":"cit0079","unstructured":"Pharmaceuticals M Marinus pharmaceuticals reports topline ganaxolone phase 2 open-label results in tuberous sclerosis complex and receives fda orphan drug designation 2021 [cited 2021 Dec 21]. Available from: https:\/\/ir.marinuspharma.com\/news\/news-details\/2021\/Marinus-Pharmaceuticals-Reports-Topline-Ganaxolone-Phase-2-Open-Label-Results-in-Tuberous-Sclerosis-Complex-and-Receives-FDA-Orphan-Drug-Designation\/default.aspx"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9695-z"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2014.06.006"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00690-8"},{"key":"cit0083","volume-title":"Intravenous ganaxolone for the treatment of refractory status epilepticus results from an open-label, dose-finding, phase 2 study","author":"Vaitekevicius H","year":"2021"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-017-2305-x"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2014.11.002"},{"key":"cit0086","unstructured":"Curonz. Clinical Studies by Curonz 2021. [cited 2021 Dec 1]. Available from: http:\/\/www.curonz.com\/clinical.html"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(96)80023-3"},{"issue":"12","key":"cit0088","first-page":"5773","volume":"62","author":"Owen RM","journal-title":"J Med Chem"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13046"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007271"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.02.003"},{"key":"cit0092","volume-title":"Long-Term Experience with Intracerebroventricular Sodium Valproate Administration. American Epilepsy Society Meeting","author":"Cook M","year":"2021"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100326"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106567"},{"key":"cit0095","unstructured":"Therapeutics E Engage therapeutics announces phase 2b states study of staccato\u00ae alprazolam for seizure cessation meets primary endpoint 2020 [cited 2021 Dec 22]. Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/03\/12\/1999155\/0\/en\/Engage-Therapeutics-Announces-Phase-2b-StATES-Study-of-Staccato-Alprazolam-for-Seizure-Cessation-Meets-Primary-Endpoint.html#:~:text=%E2%80%9CWith%20statistically%20significant%20and%20clinically,within%20two%20hours%2C%E2%80%9D%20said%20Jaqueline"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168416"},{"issue":"1","key":"cit0097","doi-asserted-by":"crossref","first-page":"e12013","DOI":"10.1002\/trc2.12013","volume":"6","author":"Hampel H","year":"2020","journal-title":"Alzheimers Dement"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172796"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973781"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03495.x"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32500-0"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14540"},{"key":"cit0103","unstructured":"Knupp K fenfluramine demonstrates efficacy in lennox-gastaut syndrome in phase 3 results 2020. [cited 2021 Dec 25]. Available from: https:\/\/www.neurologylive.com\/view\/fenfluramine-demonstrates-efficacy-in-lennox-gastaut-syndrome-in-phase-3-results"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14965"},{"key":"cit0105","first-page":"65","volume":"6","author":"Pong AW","year":"2008","journal-title":"Biology of Siezure Susceptibility in Developing Brain"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03592.x"},{"key":"cit0107","first-page":"179","volume-title":"Inherited metabolic Epilepsies","author":"Pong AW","year":"2013"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.02980.x"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.92"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2011.01.017"},{"key":"cit0111","volume-title":"What can LGS learn (or not) from IS trials?","author":"Knupp K","year":"2021"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2011.08.010"},{"key":"cit0113","volume-title":"How can we better understand the underlying disease mechanism and\/or seizure mechanism to help LGS trials?","author":"Kessler S","year":"2021"},{"key":"cit0114","unstructured":"PrevEp P 2021 [cited Dec 25]. Available from: https:\/\/www.prevep.com\/pipeline\/"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2022.2059464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T03:13:34Z","timestamp":1726888414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2022.2059464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,2]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/14728214.2022.2059464"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2022.2059464","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}